Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 168-172

  Roche, Maria R ^a   Rudd, Pandora J ^a   Krasner, Carolyn N ^a   Matulonis, Ursula A ^a   Berlin, Suzanne T ^a   Lee, Hang ^a   Silver, Michael ^a   Tran, Chau D ^a   Seiden, Michael V ^a   Penson, Richard T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Immunotheraphy

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; BONE PAIN; CANCER RELAPSE; CELL COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; COUGHING; DRUG DOSE ESCALATION; DRUG EFFICACY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MUELLERIAN DUCT; MUSCULOSKELETAL PAIN; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 73949126823     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.075     Document Type: Article

References (23)

1. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 351 (2004) 2519-2529
2. Hawkins R.E., Roberts K., Wiltshaw E., et al. The clinical correlates of serum CA-125 in 169 patients with epithelial ovarian carcinoma. Br. J. Cancer 60 (1989) 634-637
3. Rustin G.J., van der Burg M.E., and on behalf of MRC and EORTC collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA-125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J. Clin. Oncol. 27 18s (2009) (suppl; abstr 1)
4. Penson R.T., Dignan F., Seiden M.V., et al. Attitudes to chemotherapy in patients with ovarian cancer. Gyn. Onc. 94 (2004) 427-435
5. del Carmen M.G., Fuller A.F., et al. Seiden MV phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gyn. Onc. 91 (2003) 596-602
6. Spitler L.E., Grossbard M.L., Erstoff M.S., et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony stimulating factor. J. Clin. Oncol. 18 (2000) 1614-1621
7. Soiffer R., Hodi F.S., Haluska F., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21 (2003) 3343-3350
8. Salgia R., Lynch T., Skarin A., et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21 (2003) 624-630
9. Butler M.O., Seiden M., Mihm M., et al. A phase I study of vaccination with lethally irradiated, autologous ovarian cancer cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (GVAX). Proc. Am. Soc. Clin. Oncol. 21 (2002) Abs 1840
10. Small E.J., Reese D.M., and Um B. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 5 (1999) 1738-1744
11. Rini B.I., Weinberg V., Bok R., and Small E.J. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J. Clin. Oncol. 21 (2003) 99-105
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
13. Rustin G.J., Bast Jr. R.C., Kelloff G.J., et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 10 (2004) 3919-3926
14. Markman M., Webster K., Zanotti K., Rohl J., and Belinson J. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gyn. Onc. 93 (2004) 390-393
15. Yin B.W., and Lloyd K.O. Molecular cloning of the CA-125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 276 (2001) 27371-27375
16. Bagan P., Berna P., Assouad J., Hupertan V., Le Pimpec Barthes F., and Riquet M. Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur. Respir. J. 31 (2008) 140-142
17. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. NEJM 2003;348:203-13.
18. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 9 (2004 Sep) 942-949 Epub 2004 Aug 22
19. Ruter J., Barnett B.G., Kryczek I., et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front. Biosci. 14 (2009) 1761-1770
20. Diefenbach C.S., Gnjatic S., Sabbatini P., et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res. 14 (2008) 2740-2748
21. Odunsi K., Qian F., Matsuzaki J., et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12837-12842
22. Hodi F.S., Butler M., Oble D.A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3005-3010
23. Chuang C.M., Monie A., Wu A., Mao C.P., and Hung C.F. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum. Gene Ther. 20 (2009) 303-313